HEUKING advised TecDAX-listed Eckert & Ziegler SE on the spin-off of Pentixapharm, including Pentixapharm‘s IPO on the Frankfurt stock exchange and IPO capital increase
A team led by HEUKING partner Michael Neises, Frankfurt, and Christopher Görtz, Cologne, provided legal and tax advice to TecDax-listed Eckert & Ziegler SE on the spin-off of Pentixapharm AG and the subsequent IPO of Pentixapharm Holding AG on the regulated market of the Frankfurt stock exchange. This is the first spin-off transaction in the regulated market (with securities prospectus) with additional IPO capital increase. The HEUKING team consisted of a cross-practice group team from seven HEUKING offices, which provided comprehensive legal and tax advice under the leadership of Michael Neises and Christopher Görtz. BankM AG, Frankfurt, accompanied the transaction as Sole Global Coordinator and Sole Bookrunner. The transaction was handled in-house by Michael Schmolinske (General Counsel, Eckert & Ziegler SE) and Sebastian Bloszyk (Pentixapharm).
Pentixapharm AG is a clinical-stage radiopharmaceutical development company founded in 2019 with its headquarters in Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. The specific binding of the ligand to the pathological surface structure of the target cell is identical for both diagnosis and therapy, enabling a theranostic mode of action.
The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific and industrial use. The core businesses of the Group are cancer therapy, industrial radiometry and nuclear-medical imaging. The two business segments are: Medical and Isotope Products. Eckert & Ziegler was founded in 1997 as a holding company. The oldest subsidiary, Eckert & Ziegler BEBIG GmbH, was preceded by the Zentralinstitut für Isotopentechnik, a research institute of the former Academy of Sciences of the GDR. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Counsel Eckert & Ziegler SE
HEUKING:
Michael Neises, Frankfurt,
Christopher Görtz (both Lead, both Corporate/M&A), Cologne,
Berlin
Christoph Wagner (Health Care)
Düsseldorf
Christoph Hexel (Employment Law)
Frankfurt
Dr. André Hofmann, LL.M. (Finance),
Frank Hollstein,
Finn-Michael Liebscher (both Corporate),
Thalia Roth (Finance)
Hamburg
Dr. Henrik Lay,
Simon Pommer, LL.M. (both Tax)
Cologne
Dominik Eickemeier (IP, Media & Technology),
Dr. Thorsten Kuthe,
Miriam Schäfer,
Stefan Westerheide, LL.M. oec (all Corporate/M&A),
Svea Kunz (IP, Media & Technology),
Tatiana Vorotnitskaya, k.i.n.,
Meike Daniels,
Magdalena Köster (all Corporate/M&A)
München
Dr. Helge-Torsten Wöhlert (Corporate/M&A),
Catarina Angelika Seemann, LL.M.,
Kim Anna Schwick (both Health Care)
Stuttgart
Julian Weidenhammer, LL.M. (Corporate/M&A)
